Vistagen Therapeutics (NASDAQ:VTGN) Share Price Crosses Below 50-Day Moving Average of $4.69

Vistagen Therapeutics, Inc. (NASDAQ:VTGN - Get Free Report)'s stock price passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $4.69 and traded as low as $4.52. Vistagen Therapeutics shares last traded at $4.66, with a volume of 135,163 shares trading hands.

Vistagen Therapeutics Trading Down 4.5 %

The stock has a fifty day moving average price of $4.68 and a two-hundred day moving average price of $4.52.

Vistagen Therapeutics (NASDAQ:VTGN - Get Free Report) last issued its quarterly earnings results on Tuesday, February 13th. The company reported ($0.22) EPS for the quarter, beating analysts' consensus estimates of ($0.31) by $0.09. The company had revenue of $0.41 million for the quarter, compared to analyst estimates of $0.73 million. Vistagen Therapeutics had a negative return on equity of 72.10% and a negative net margin of 3,073.51%. On average, sell-side analysts forecast that Vistagen Therapeutics, Inc. will post -1.56 EPS for the current year.

Hedge Funds Weigh In On Vistagen Therapeutics

Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC acquired a new position in shares of Vistagen Therapeutics in the fourth quarter worth about $48,000. Raymond James & Associates acquired a new position in Vistagen Therapeutics during the third quarter valued at $52,000. BML Capital Management LLC increased its holdings in shares of Vistagen Therapeutics by 50.0% in the 4th quarter. BML Capital Management LLC now owns 150,000 shares of the company's stock valued at $771,000 after purchasing an additional 50,000 shares during the period. AdvisorShares Investments LLC purchased a new stake in shares of Vistagen Therapeutics in the fourth quarter worth approximately $279,000. Finally, Blair William & Co. IL acquired a new stake in shares of Vistagen Therapeutics during the third quarter worth approximately $446,000. Institutional investors own 78.39% of the company's stock.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.